PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629267
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629267
Plasma Therapy Market size was valued at USD 468.89 Million in 2023, expanding at a CAGR of 14.5% from 2024 to 2032.
The Plasma Therapy Market involves using plasma-derived products, including immunoglobulins, clotting factors, and albumin, for treating various medical conditions, such as immune deficiencies, bleeding disorders, and autoimmune diseases. The growing demand for plasma therapy is spurred by an increasing prevalence of chronic conditions, with the World Health Organization reporting that over 350 million people worldwide suffer from autoimmune diseases. Additionally, the rising number of trauma cases and surgical interventions requiring plasma-based treatments fuel market growth. However, the market faces challenges such as the high cost of plasma collection and processing, along with limited donor availability. Despite these challenges, opportunities are emerging with advancements in plasma fractionation technology, which allows for higher yields of therapeutic proteins, and the expansion of plasma donation programs in developing regions. Furthermore, the growing adoption of plasma therapies in the treatment of COVID-19 and other infectious diseases is contributing to market expansion.
Plasma Therapy Market- Market Dynamics
Rising Prevalence of Autoimmune Diseases Drives Growth in the Plasma Therapy Market
The demand for plasma therapy is increasing due to the rising prevalence of autoimmune diseases, which affect millions globally. According to the American Autoimmune Related Diseases Association, nearly 50 million Americans suffer from autoimmune disorders, with conditions like rheumatoid arthritis and lupus becoming more common. Plasma-derived therapies, such as immunoglobulins and clotting factors, are critical in managing these diseases by boosting the immune system and preventing organ damage. Additionally, ongoing advancements in plasma fractionation technology and the growing availability of plasma donation programs are further supporting the expansion of the market. With autoimmune diseases projected to rise globally, the market for plasma therapies is expected to experience significant growth in the coming years.
Plasma Therapy Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 14.5% over the forecast period (2024-2032)
Based on product type segmentation, Pure PRP was predicted to show maximum market share in the year 2023
Based on Source segmentation, Autologous Plasma was the leading type in 2023
Based on region, North America was the leading revenue generator in 2023
The Global Plasma Therapy Market is segmented based on Product Type, Source, Application, End-User, and Region.
The market is divided into four categories based on product type: Pure PRP (Platelet-Rich Plasma), Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin, and Leukocyte-rich Fibrin. Pure PRP leads the market due to its widespread use in regenerative medicine and aesthetics, followed by Leukocyte-Rich PRP, known for its enhanced healing properties. Pure Platelet-Rich Fibrin follows, with Leukocyte-rich Fibrin remaining a niche option in specific treatments.
The market is divided into two categories based on Source: Autologous Plasma and Allogeneic Plasma. Autologous plasma leads due to its lower risk of immune reactions and is preferred in most therapeutic applications. Allogeneic plasma follows, used in certain clinical treatments but limited by the need for compatibility and the potential for immune-related complications.
Plasma Therapy Market- Geographical Insights
The Plasma Therapy Market shows substantial geographical variation, with North America leading the market, driven by advanced healthcare infrastructure and high demand for plasma-derived therapies. The United States is a major contributor due to its extensive plasma donation network and a large population suffering from autoimmune diseases. Europe follows closely, with countries like Germany and the UK having well-established plasma collection systems and a growing focus on treating chronic conditions through plasma therapies. The Asia-Pacific region is experiencing rapid growth, particularly in countries like China and India, where increasing healthcare investments and rising healthcare awareness are expanding the adoption of plasma therapies. Latin America and the Middle East & Africa are witnessing growing demand due to rising healthcare access and increasing awareness about plasma therapy benefits. Government initiatives to improve plasma donation systems are expected to further drive market expansion in these regions.
The Plasma Therapy Market is highly competitive, with key players focusing on expanding their product portfolios and enhancing plasma collection networks. Major companies in the market include Grifols, CSL Behring, Octapharma, Kedrion Biopharma, and Baxter International, which dominate the plasma-derived therapies sector. These companies are investing heavily in research and development to introduce new and improved plasma-derived products, including immunoglobulins, albumin, and clotting factors, to cater to the increasing demand for plasma therapies. Additionally, strategic collaborations and acquisitions are common as companies seek to expand their global reach and enhance production capabilities. For example, Grifols and CSL Behring have strengthened their positions through acquisition and regional expansion. Moreover, regulatory bodies like the FDA and EMA play a crucial role in ensuring the safety and efficacy of plasma therapies, fostering a competitive environment that emphasizes innovation and quality control in the market.
In October 2021, BioLife Plasma Services opened a new plasma center in Worcester, United States, to address the increasing demand for plasma-derived therapies, enhancing their capacity to collect and provide plasma for treatments.
In August 2021, Biotest AG opened its sixth plasma collection center in the Czech Republic, aiming to secure a long-term plasma supply and meet the growing demand for plasma-derived therapies through expanded collection capabilities.